In May, FDA approved Voquenza (vonoprazan fumarate), in combination with anti-biotics, for H.pylori infection. In March, Phathom Pharmaceuticals submitted an NDA to FDA for the use of vonoprazan ...

Vonoprazan continued to be noninferior in maintenance of healing at 24 weeks for both the 10 mg (89.2%) and 20 mg (90.7%) doses versus lansoprazole (79.7%).

The FDA approved vonoprazan (Voquezna) for all grades of erosive gastroesophageal reflux disease (GERD) and heartburn relief associated with the condition, Phathom Pharmaceuticals announced on ...

Phathom Pharmaceuticals announces vonoprazan NDA submission for non-erosive GERD. News release. Phathom Pharmaceuticals. September 26, 2023. Accessed December 6, 2023.

Find patient medical information for Voquezna Dual Pak (vonoprazan and amoxicillin) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Among those on vonoprazan throughout the study, mean percentages of 24-hour heartburn-free days were 62.6% for the 10 mg dose (n = 247), and 60.7% for the 20 mg dose (n = 235).

Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis ...

The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.

The application is supported by data from the pivotal phase 3 PHALCON-EE trial which compared the efficacy and safety of vonoprazan to lansoprazole in patients with erosive esophagitis.